Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

623 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD36 deficiency induced by antiretroviral therapy.
Serghides L, Nathoo S, Walmsley S, Kain KC. Serghides L, et al. Among authors: walmsley s. AIDS. 2002 Feb 15;16(3):353-8. doi: 10.1097/00002030-200202150-00006. AIDS. 2002. PMID: 11834946 Clinical Trial.
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713. J Infect Dis. 2008. PMID: 18476292 Clinical Trial.
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, et al. J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523. J Infect Dis. 2008. PMID: 18476293 Clinical Trial.
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
SMART Study Group; El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD. SMART Study Group, et al. Ann Intern Med. 2008 Sep 2;149(5):289-99. doi: 10.7326/0003-4819-149-5-200809020-00003. Ann Intern Med. 2008. PMID: 18765698 Clinical Trial.
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Fätkenheuer G, et al. N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154. N Engl J Med. 2008. PMID: 18832245 Free article.
Interleukin-2 therapy in patients with HIV infection.
INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee; Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D. INSIGHT-ESPRIT Study Group, et al. N Engl J Med. 2009 Oct 15;361(16):1548-59. doi: 10.1056/NEJMoa0903175. N Engl J Med. 2009. PMID: 19828532 Free PMC article. Clinical Trial.
623 results